Pfizer and Medivation reportedly close to $14bn deal
US pharmaceutical giant Pfizer is reportedly in advanced talks to buy cancer drug company Medivation for about $14bn. San Francisco-based Medivation produces the prostate-cancer treatment Xtandi. France’s Sanofi was trying to buy Medivation, and Merck & Co and Celgene were also said be the queue. On Sunday Pfizer had agreed in principle to pay about…